Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Daniil Gataulin has reiterated a Buy rating for Cognition Therapeutics (NASDAQ:CGTX) and maintained a price target of $11.
October 31, 2024 | 1:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital has reiterated its Buy rating for Cognition Therapeutics, maintaining a price target of $11, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and maintenance of a price target by Chardan Capital suggests continued confidence in Cognition Therapeutics' potential. This is likely to positively influence investor sentiment and could lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100